<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237821</url>
  </required_header>
  <id_info>
    <org_study_id>CS1007033A</org_study_id>
    <nct_id>NCT01237821</nct_id>
  </id_info>
  <brief_title>Comparing OTC Acne Treatment to Prescription Regimen</brief_title>
  <official_title>A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loreal USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out the safety and efficacy of two acne creams, Effaclar
      and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA
      approved for the treatment of acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many products on the market to treat facial acne. The medication that this study
      will be evaluating, Benzaclin and Retin-A have been approved by the FDA and is available by
      prescription, Effaclar is an over the counter product. This study will hopefully recognize a
      treatment combination that is effective in reducing acne vulgaris in adults 18-50.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Tolerability Assessment: Erythema</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for Erythema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Tolerability Assessment: Edema</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for Edema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Tolerability Assessment: Dryness</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for Dryness on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Tolerability Assessment: Peeling</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for Peeling on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Skin Tone (Clarity)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for skin tone (clarity) on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Skin Smoothness</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for skin smoothness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Skin Brightness</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for skin brightness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Appearance of Pores</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for the appearance of pores on a 10-point visual analog scale,with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Overall Appearance</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for overall appearance on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Skin Assessment: Global Acne Assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>The facial skin was assessed for global acne assessment on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Open Comedones</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Closed Comedones</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial closed comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Papules</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Pustules</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial pustules and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Noninflammatory Lesions</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial noninflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Inflammatory Lesions</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for facial inflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Lesion Counts: Total Lesion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participants were assessed for all facial lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Tolerability of Irritation Assessment (Participant Assessed): Stinging</measure>
    <time_frame>16 weeks</time_frame>
    <description>Irritation stinging was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Tolerability of Irritation Assessment (Participant Assessed): Tingling</measure>
    <time_frame>16 weeks</time_frame>
    <description>Irritation tingling was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Tolerability of Irritation Assessment (Participant Assessed): Itching</measure>
    <time_frame>16 weeks</time_frame>
    <description>Irritation itching was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Tolerability of Irritation Assessment (Participant Assessed): Burning</measure>
    <time_frame>16 weeks</time_frame>
    <description>Irritation burning was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BenzaClin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with &gt; or equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>effaclar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with &gt; or equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BenzaClin</intervention_name>
    <description>Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
    <arm_group_label>BenzaClin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effaclar</intervention_name>
    <description>Topical, Bid, 12 weeks</description>
    <arm_group_label>effaclar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:males and females ages 18-50, mild to moderate acne vulgaris with &gt; or
        equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid
        excessive sun exposure or tanning beds throughout the study

        Exclusion Criteria:Participants who have another skin condition that will interfere with
        lesion counting or assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Oresajo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loreal USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <results_first_submitted>April 24, 2017</results_first_submitted>
  <results_first_submitted_qc>June 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Amy Longenecker</investigator_full_name>
    <investigator_title>RN, CCRC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BenzaClin</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Effaclar</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BenzaClin</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Effaclar</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.53" spread="9.81"/>
                    <measurement group_id="B2" value="32.41" spread="9.30"/>
                    <measurement group_id="B3" value="30.92" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Tolerability Assessment: Erythema</title>
        <description>Participants were assessed for Erythema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Tolerability Assessment: Erythema</title>
          <description>Participants were assessed for Erythema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Tolerability Assessment: Edema</title>
        <description>Participants were assessed for Edema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Tolerability Assessment: Edema</title>
          <description>Participants were assessed for Edema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Tolerability Assessment: Dryness</title>
        <description>Participants were assessed for Dryness on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Tolerability Assessment: Dryness</title>
          <description>Participants were assessed for Dryness on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Tolerability Assessment: Peeling</title>
        <description>Participants were assessed for Peeling on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Tolerability Assessment: Peeling</title>
          <description>Participants were assessed for Peeling on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Skin Tone (Clarity)</title>
        <description>The facial skin was assessed for skin tone (clarity) on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Skin Tone (Clarity)</title>
          <description>The facial skin was assessed for skin tone (clarity) on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.9" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Skin Smoothness</title>
        <description>The facial skin was assessed for skin smoothness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Skin Smoothness</title>
          <description>The facial skin was assessed for skin smoothness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.9" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Skin Brightness</title>
        <description>The facial skin was assessed for skin brightness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Skin Brightness</title>
          <description>The facial skin was assessed for skin brightness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Appearance of Pores</title>
        <description>The facial skin was assessed for the appearance of pores on a 10-point visual analog scale,with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Appearance of Pores</title>
          <description>The facial skin was assessed for the appearance of pores on a 10-point visual analog scale,with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.2" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Overall Appearance</title>
        <description>The facial skin was assessed for overall appearance on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Overall Appearance</title>
          <description>The facial skin was assessed for overall appearance on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.9" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Skin Assessment: Global Acne Assessment</title>
        <description>The facial skin was assessed for global acne assessment on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Skin Assessment: Global Acne Assessment</title>
          <description>The facial skin was assessed for global acne assessment on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Open Comedones</title>
        <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Open Comedones</title>
          <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Open Comedone Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O2" value="8.3" lower_limit="1" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Closed Comedones</title>
        <description>Participants were assessed for facial closed comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Closed Comedones</title>
          <description>Participants were assessed for facial closed comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Closed Comedone Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="5" upper_limit="38"/>
                    <measurement group_id="O2" value="23" lower_limit="5" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="5" upper_limit="24"/>
                    <measurement group_id="O2" value="14.8" lower_limit="7" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="1" upper_limit="15"/>
                    <measurement group_id="O2" value="13.7" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="O2" value="9.8" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="8.4" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Papules</title>
        <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Papules</title>
          <description>Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Papule Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="6" upper_limit="26"/>
                    <measurement group_id="O2" value="15.7" lower_limit="4" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="2" upper_limit="19"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O2" value="6.6" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="5.8" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O2" value="4.5" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Pustules</title>
        <description>Participants were assessed for facial pustules and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Pustules</title>
          <description>Participants were assessed for facial pustules and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Pustules Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="3.9" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Noninflammatory Lesions</title>
        <description>Participants were assessed for facial noninflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Noninflammatory Lesions</title>
          <description>Participants were assessed for facial noninflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Noninflammatory Lesion Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="6" upper_limit="61"/>
                    <measurement group_id="O2" value="31.3" lower_limit="10" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="5" upper_limit="48"/>
                    <measurement group_id="O2" value="19.6" lower_limit="5" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="2" upper_limit="26"/>
                    <measurement group_id="O2" value="17.3" lower_limit="4" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O2" value="13.3" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="9.3" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="0" upper_limit="19"/>
                    <measurement group_id="O2" value="10.9" lower_limit="0" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Inflammatory Lesions</title>
        <description>Participants were assessed for facial inflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Inflammatory Lesions</title>
          <description>Participants were assessed for facial inflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Inflammatory Lesion Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="6" upper_limit="32"/>
                    <measurement group_id="O2" value="19.6" lower_limit="5" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="5" upper_limit="22"/>
                    <measurement group_id="O2" value="10.4" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O2" value="7.9" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="6.7" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="6.2" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facial Lesion Counts: Total Lesion</title>
        <description>Participants were assessed for all facial lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Lesion Counts: Total Lesion</title>
          <description>Participants were assessed for all facial lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>Total Lesion Count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="12" upper_limit="66"/>
                    <measurement group_id="O2" value="51.0" lower_limit="18" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" lower_limit="10" upper_limit="59"/>
                    <measurement group_id="O2" value="30.0" lower_limit="8" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="10" upper_limit="48"/>
                    <measurement group_id="O2" value="25.1" lower_limit="13" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="2" upper_limit="31"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="2" upper_limit="22"/>
                    <measurement group_id="O2" value="13.7" lower_limit="3" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="5" upper_limit="34"/>
                    <measurement group_id="O2" value="17.0" lower_limit="2" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Stinging</title>
        <description>Irritation stinging was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Stinging</title>
          <description>Irritation stinging was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Tingling</title>
        <description>Irritation tingling was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Tingling</title>
          <description>Irritation tingling was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Itching</title>
        <description>Irritation itching was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Itching</title>
          <description>Irritation itching was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Burning</title>
        <description>Irritation burning was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
        <group_list>
          <group group_id="O1">
            <title>Effaclar</title>
            <description>Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benzaclin</title>
            <description>BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Tolerability of Irritation Assessment (Participant Assessed): Burning</title>
          <description>Irritation burning was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.</description>
          <population>Male and female 18-50 years old, mild to moderate acne vulgaris with &gt;15 inflammatory lesions (papules/pustules) and &gt;20 non-inflammatory lesions (black heads/white heads) on the face.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Effaclar</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>BenzaClin</title>
          <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Diane Thiboutot</name_or_title>
      <organization>Penn State Hershey Medical Center</organization>
      <phone>717-531-1513</phone>
      <email>dthiboutot@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

